| Literature DB >> 23364337 |
Xianguang Chen1, Takefumi Mori, Qi Guo, Chunyan Hu, Yusuke Ohsaki, Yoshimi Yoneki, Wanjun Zhu, Yue Jiang, Satoshi Endo, Keisuke Nakayama, Susumu Ogawa, Masaaki Nakayama, Toshio Miyata, Sadayoshi Ito.
Abstract
One major precursor of carbonyl stress, methylglyoxal (MG), is elevated in the plasma of chronic kidney disease (CKD) patients, and this precursor contributes to the progression of vascular injury, hypertension and renal injury in diabetic nephropathy patients. This molecule induces salt-sensitive hypertension via a reactive oxygen species-mediated pathway. We examined the role of MG in the pathogenesis of hypertension and cardio-renal injury in Dahl salt-sensitive (Dahl S) rats, which is a rat model of CKD. Nine-week-old Dahl S rats were fed a 1% NaCl diet, and 1% MG was added to their drinking water for up to 12 weeks. Blood pressure and cardio-renal injuries were compared with rats treated with tap water alone. The angiotensin II receptor blocker (ARB), candesartan (10 mg kg(-1) day(-1)), was administered to MG Dahl S rats to determine the impact of this drug on the pathogenesis of MG-induced CKD. A progressive increase in systolic blood pressure was observed (123±1-148±5 mm Hg) after 12 weeks of MG administration. MG administration significantly increased urinary albumin excretion, glomerular sclerosis, tubular injury, myocardial collagen content and cardiac perivascular fibrosis. MG also enhanced the renal expression of Nɛ-carboxyethyl-lysine (an advanced glycation end product), 8-hydroxydeoxyguanosine (a marker of oxidative stress), macrophage (ED-1) positive cells (a marker of inflammation) and nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase activity. Candesartan treatment for 4 weeks significantly reduced these parameters. These results suggest that MG-induced hypertension and cardio-renal injury and increased inflammation and carbonyl and oxidative stress, which were partially preventable by an ARB.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23364337 PMCID: PMC3619051 DOI: 10.1038/hr.2012.204
Source DB: PubMed Journal: Hypertens Res ISSN: 0916-9636 Impact factor: 3.872
Figure 1Sequential systolic blood pressure (SBP) values measured using the tail-cuff method during the 12-week experimental period in protocol 1 (a); and during the 4-week experimental period in protocol 2 (b). Twenty-four-hour SBP values from the femoral artery measured using a radio-telemetry transmitter system (c). Protocol 1: control (n=8), treatment with tap water; MG-12W (n=9), treatment with 1% methylglyoxal (MG) in drinking water for 12 weeks. Protocol 2: MG-4W (n=8), treatment with 1% MG in drinking water; MG+CAND (n=12), co-treatment with MG and candesartan for 4 weeks. Data are presented as means±s.e. *P<0.05 vs. control group and data of MG-12W at 0 week; †P<0.05 vs. MG+CAND group and data of MG-4W at 0 week. ‡P<0.05 vs. control group.
Figure 2Twenty-four-hour urinary albumin excretion during the 12-week experimental period in protocol 1 (a), and during the 4-week experimental period in protocol 2 (b). Protocol 1: control (n=8), treatment with tap water; MG-12W (n=9), treatment with 1% methylglyoxal (MG) in drinking water for 12 weeks. Protocol 2: MG-4W (n=8), treatment with 1% MG in drinking water; MG+CAND (n=12), co-treatment with MG and candesartan for 4 weeks. Data are presented as means±s.e. *P<0.05 vs. control or MG+CAND group; †P<0.05 vs. data of MG-12W or MG-4W group at 0 week.
Parameters of kidney and heart tissue in protocols 1 and 2
| GSI | 1.86±0.06 | 2.08±0.07* | 1.69±0.05 | 1.35±0.03† |
| OPN-positive area (% of cortex and outer medulla) | 0.50±0.10 | 1.49±0.12* | 1.18±0.28 | 0.36±0.08† |
| ED-1 in glomerulus (cells per glomerulus) | 0.55±0.09 | 1.34±0.15* | 1.26±0.09 | 0.97±0.09† |
| ED-1 in interstitial area (cells per × 400 field) | 1.47±0.25 | 3.37±0.17* | 2.15±0.06 | 1.16±0.13† |
| CEL-positive area (% of cortex and outer medulla) | 2.8±0.5 | 17.7±5.5* | 7.1±0.9 | 2.8±0.3† |
| 8-OhdG-positive area (% of cortex and outer medulla) | 2.91±0.12 | 4.10±0.22* | 2.10±0.25 | 1.17±0.21† |
| NADPH oxidase activity (c.p.m. per 200 mg protein) | 86±3 | 121±10* | 143±6 | 124±4† |
| Total collagen content (%) | 3.5±0.3 | 6.9±0.6* | 4.4±0.4 | 1.4±0.1† |
| Perivascular fibrosis score | 1.8±0.1 | 2.5±0.2* | 1.7±0.1 | 1.2±0.2† |
Abbreviations: CEL, Nɛ-carboxyethyl-lysine; ED-1, macrophage; GSI, glomerular sclerosis index; MG, methylglyoxal; NADPH, nicotinamide adenine dinucleotide phosphate; OPN, osteopontin; 8-OHdG, 8-hydroxydeoxyguanosine.
Protocol 1: control (n=8), tap water; MG-12W (n=9), treatment with 1% MG in drinking water for 12 weeks. Protocol 2: MG-4W (n=8), treatment with 1% MG in drinking water; MG+CAND (n=12), co-treatment with MG and candesartan for 4 weeks. Data are presented as means±s.e. *P<0.01 vs. control group; †P<0.05 vs. MG-4W group.
Figure 3Images of glomerular sclerosis stained with the Elastica–Masson method and immunostained with Nɛ-carboxyethyl-lysine (CEL), 8-hydroxydeoxyguanosine (8-OhdG), osteopontin (OPN), ED-1 antibodies (black arrowheads) and receptor for advanced glycation end products (RAGEs) in the kidney (a), and collagen deposition in the myocardial interstitial space and cardiac perivascular fibrosis in the heart (b), in protocol 1 (control and MG-12W groups treated for 12 weeks), and protocol 2 (MG-4W, MG+CAND, and CAND groups treated for 4 weeks).